Coherus Oncology, Inc. Operating Income Loss

• Coherus Oncology, Inc. showed an increase of +9.3% in Operating Income Loss from 2024 to 2025.
• This data is from Coherus Oncology, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
• XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 14 years of available data (2012 to 2025), Coherus Oncology, Inc.'s Operating Income Loss has declined by 370.3%.
• Historical annual values: Fiscal year 2025: -$181.13 million | Fiscal year 2024: -$199.65 million | Fiscal year 2023: -$203.20 million | Fiscal year 2022: -$256.88 million | Fiscal year 2021: -$263.86 million | Fiscal year 2020: $156.32 million | Fiscal year 2019: $107.77 million | Fiscal year 2018: -$204.42 million | Fiscal year 2017: -$232.14 million | Fiscal year 2016: -$115.93 million | Fiscal year 2015: -$219.07 million | Fiscal year 2014: -$64.68 million | Fiscal year 2013: -$35.99 million | Fiscal year 2012: -$38.52 million.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026